Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,137 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo for Active Clear all
Terminated Phase 2 Interventional Results available

Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients

NCT03617445
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
FMT oral capsule, Oral Vancomycin, FMT oral placebo, Oral Vancomycin placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 21, 2026, 11:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Relief 24_RLN: A Study Assessing the Impact of Health and Wellness Products on Pain and Related Health Outcomes.

NCT07160712
View directory record Official record
Conditions
Pain
Interventions
Relief Product Placebo Control, Relief Active Product 1, Relief Active Product 2, Relief Active Product 3
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 21, 2026, 11:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

NCT01456936
View directory record Official record
Conditions
Smoking Cessation
Interventions
Placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
8,144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
77
States / cities
Mobile, Alabama • Phoenix, Arizona • Encino, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2016 · Synced Oct 21, 2026, 11:03 AM EDT
Recruiting Phase 4 Interventional

Comparative Effectiveness of Available Treatments for Sinus and Ear Infections in Children (Acute Otitis Media)

NCT07730814
View directory record Official record
Conditions
Acute Otitis Media (AOM)
Interventions
Amoxicillin, Amoxicillin-Clavulanate, Amoxicillin Placebo, Amoxicillin-Clavulanate Placebo
Drug
Lead sponsor
Nader Shaikh
Other
Eligibility
6 Months to 36 Months
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
5
States / cities
Denver, Colorado • Durham, North Carolina • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

Effects of Sacrosidase and Placebo in Subjects With Fructan Intolerance

NCT05703009
View directory record Official record
Conditions
Fructan Intolerance
Interventions
Sacrosidase Oral Solution, Placebo
Drug
Lead sponsor
QOL Medical, LLC
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 21, 2026, 11:03 AM EDT
Recruiting Phase 2 Interventional

Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

NCT05604131
View directory record Official record
Conditions
Acute Myocardial Infarction Type 1
Interventions
Deferiprone Tablets, Placebo
Drug
Lead sponsor
Rohan Dharmakumar
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
2
States / cities
Indianapolis, Indiana • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 21, 2026, 11:03 AM EDT
Recruiting Phase 3 Interventional

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

NCT05125302
View directory record Official record
Conditions
Migraine
Interventions
Ubrogepant, Placebo-Matching Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
125
States / cities
Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 21, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Resveratrol for Improved Performance in the Elderly

NCT01126229
View directory record Official record
Conditions
Memory
Interventions
Placebo, Low dose Resveratrol, High dose Resveratrol
Dietary Supplement · Drug
Lead sponsor
University of Florida
Other
Eligibility
65 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 21, 2026, 11:03 AM EDT
Recruiting Not applicable Interventional

Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia

NCT07191119
View directory record Official record
Conditions
Survivor of Childhood Cancer, Insomnia, Acute Lymphoblastic Leukemia (ALL)
Interventions
Soterix tVNS device, Soterix tVNS device (sham programmed), Sleep Quality, Neurocognitive and mental health outcomes
Device · Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
20 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 21, 2026, 11:03 AM EDT
Completed Phase 4 Interventional Results available

Decreasing Rates of Intraurethral Catheterization Postoperatively in Spine Surgery

NCT02919436
View directory record Official record
Conditions
Post-operative Urinary Retention
Interventions
Tamsulosin, Placebo
Drug
Lead sponsor
Anand Rughani, MD
Other
Eligibility
50 Years to 85 Years · Male only
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 21, 2026, 11:03 AM EDT
Completed Phase 2 Interventional

ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis

NCT00048321
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ISIS 104838
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
26
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 21, 2026, 11:03 AM EDT
Completed Phase 2 Interventional

Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel

NCT03994406
View directory record Official record
Conditions
Contact Lens Discomfort, Contact Lens-induced Corneal Disorder, Contact Lens Acute Red Eye, Contact Lens-induced Corneal Fluorescein Staining
Interventions
CLM2 topical gel, Placebo topical gel
Drug
Lead sponsor
Glia, LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 21, 2026, 11:03 AM EDT
Suspended Phase 2 Interventional

Novel Intervention for Chronic Complex TBI in OEF/OIF/OND Veterans

NCT05671692
View directory record Official record
Conditions
Traumatic Brain Injury, TBI
Interventions
Pregnenolone, Placebo
Drug
Lead sponsor
Christine Marx, MD
Other
Eligibility
21 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 21, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction

NCT01107236
View directory record Official record
Conditions
Healthy
Interventions
IW-6118, Matching Placebo, Naproxen Sodium
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 30 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 21, 2026, 11:03 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration

NCT03034772
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions
Dorzolamide-timolol, Artificial tears
Drug · Other
Lead sponsor
Wills Eye
Other
Eligibility
45 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Palo Alto, California • Boston, Massachusetts • Royal Oak, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Oct 21, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

NCT05055128
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
X842, X842 Dummy, Lansoprazole, Lansoprazole Dummy
Drug
Lead sponsor
Cinclus Pharma Holding AB
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 11:03 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis

NCT04203498
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Nabiximols, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Port Charlotte, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 21, 2026, 11:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cassia Cinnamon for Glucose Uptake in Young Women

NCT00951639
View directory record Official record
Conditions
Insulin Resistance, Impaired Glucose Tolerance, Prediabetes
Interventions
Cassia cinnamon, 50 minutes exercise, Cellulose Powder
Dietary Supplement · Procedure
Lead sponsor
Baylor University
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 21, 2026, 11:03 AM EDT
Completed Phase 4 Interventional Results available

Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease

NCT00526630
View directory record Official record
Conditions
Parkinson's Disease, Gait Impairment
Interventions
Methylphenidate (MPD), Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
35 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 21, 2026, 11:03 AM EDT
Active, not recruiting Phase 2 Interventional

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

NCT02768363
View directory record Official record
Conditions
Prostate Cancer
Interventions
aglatimagene besadenovec, placebo, valacyclovir
Biological · Drug
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Golden, Colorado • Chicago, Illinois • New Orleans, Louisiana + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 11:03 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

NCT03970837
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Tofacitinib, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
64
States / cities
Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 21, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT01496365
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
DS-5565 tablet, pregabalin capsule, Placebo tablet, placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
78
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 21, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

NCT02727699
View directory record Official record
Conditions
Dementia, Alzheimer Type
Interventions
Xanamem™, Placebo (for Xanamem™)
Drug
Lead sponsor
Actinogen Medical
Industry
Eligibility
50 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • Poway, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 21, 2026, 11:03 AM EDT
Completed Phase 4 Interventional

Amantadine for Treatment of Symptoms of the Post-traumatic Confusional State

NCT00693121
View directory record Official record
Conditions
Traumatic Brain Injury, Posttraumatic Confusional State, Delirium
Interventions
Amantadine hydrochloride, Placebo capsule
Drug
Lead sponsor
Methodist Rehabilitation Center
Other
Eligibility
16 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 21, 2026, 11:03 AM EDT